Neurological manifestations of dengue infectionTom Solomon, Nicholas J. White, Jeremy Farrar et al.|The Lancet|2000Cited by 637
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health OrganizationMinal Patel, Daniel R. Feikin, Isabel Bergeri et al.|Vaccine|2021Cited by 156
Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Alexander C. Schmidt, Kirsten E. Lyke et al.|American Journal of Tropical Medicine and Hygiene|2020Cited by 17
Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I StudyClemente Díaz, Stephen J. Thomas, Michael Koren et al.|American Journal of Tropical Medicine and Hygiene|2020Cited by 15